Clarus Therapeutics, a men’s health specialty pharmaceutical company, has started dosing patients in a Phase lll clinical trial (inTUne) of jatenzo to treat hypogonadism in males.

Currently under development, jatenzo is an oral testosterone replacement therapy and a T prodrug that is expected treat men diagnosed with testosterone deficiency together with an associated medical condition, also known as hypogonadism.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Clarus noted that inTUne is a multicentre, randomised, open-label, trial designed to evaluate the efficacy and safety of jatenzo in adult hypogonadal male subjects.

During the trail, an active comparator group will receive axiron, a topical testosterone formulation.

"We believe jatenzo has the potential to safely and effectively expand treatment options for men who need T-replacement therapy."

Around 180 subjects will be randomly assigned to receive open-label treatment in a 3:1 ratio of oral jatenzo to Axiron.

The primary efficacy time point for assessment of average T concentrations occurs on day 105 of the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Clarus Therapeutics president and CEO Dr Robert Dudley said: "After productive dialogue with the FDA regarding the complete response letter issued for our jatenzo NDA, we launched the inTUne Trial, our third Phase lll trial.

"In our first two Phase lll trials of jatenzo, we successfully demonstrated efficacy and safety consistent with approved T-replacement products. We believe this additional trial will provide the supplemental data requested by the FDA and lead to approval of our NDA.

"There continues to be solid market demand for testosterone replacement products and physicians and their patients strongly favour a new oral alternative to currently approved options. Research has shown that current T-therapies have poor compliance and that men with low-T would prefer an oral alternative.

"We believe jatenzo has the potential to safely and effectively expand treatment options for men who need T-replacement therapy."